Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Staodyn

This article was originally published in The Gray Sheet

Executive Summary

Withdraws a proposed public offering registered on Feb. 9 with the Securities and Exchange Commission ("The Gray Sheet" Feb. 15, p. 13). Lynda S. Dreiling, executive vice president, says in a March 16 announcement that the firm's decision is "based on current market conditions for the securities of health care companies, and the recent decline in the market price of Staodyn common stock." The withdrawal comes five days after Staodyn announced a restructuring of the offering and a plan to extend the term of warrants due to expire in June and to reduce their exercise price. As a result of the canceled offering, Staodyn says it will not reduce the exercise price of the warrants and may not extend their term.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT000379

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel